MGTX
MeiraGTx Holdings plc
There isn't enough reported data to score MGTX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MGTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Under pressure | |
| Strong |
MGTX's profitability and balance sheet are currently strong, but its cash flow is under pressure. There isn't enough data to rate its revenue.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $8.79 | — |
| Cheap | 13x | $10.39 | +18% |
| Fair | 15x | $12.22 | +39% |
| Expensive | 19x | $15.50 | +76% |
Historical ranges are pointers, not guarantees.
MGTX has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MGTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MGTX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.80 | +$2.90 |
| Q2 2026 | $0.71 | +$2.74 |
| Q1 2026 | -$1.48 | +$0.83 |
| Q4 2025 | -$1.42 | +$0.70 |
| Q3 2025 | -$2.10 | -$0.87 |
| Q2 2025 | -$2.03 | -$0.61 |
| Q1 2025 | -$2.31 | -$1.12 |
| Q4 2024 | -$2.12 | -$0.63 |
MGTX has returned to profit: it earned $0.80 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
MGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.8M | +1074% |
| Q2 2026 | $321.4M | +8609% |
| Q4 2025 | $75.4M | +252% |
| Q3 2025 | $410K | -96% |
| Q2 2025 | $3.7M | +1209% |
| Q3 2024 | $10.9M | +114% |
| Q2 2024 | $282K | -92% |
| Q1 2024 | $697K | -79% |
MGTX's revenue is growing: $5M last quarter, up 1074% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1036% | +10196 points |
| Q2 2026 | 76% | +1290 points |
| Q1 2026 | -13931% | N/A |
| Q4 2025 | 35% | +182 points |
| Q3 2025 | -11232% | -10865 points |
| Q2 2025 | -1214% | +15066 points |
| Q4 2024 | -147% | N/A |
| Q3 2024 | -367% | +275 points |
MGTX's operating margin was −1036% last quarter, up 10196 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MGTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MGTX on profitability, with a higher operating margin.
MGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.3M | -$13.5M |
| Q2 2026 | -$38.9M | +$6.3M |
| Q1 2026 | $15.8M | +$54.3M |
| Q4 2025 | $46.4M | +$70.9M |
| Q3 2025 | -$12.8M | +$12.9M |
| Q2 2025 | -$45.2M | -$24.4M |
| Q1 2025 | -$38.5M | -$119K |
| Q4 2024 | -$24.5M | -$6.9M |
MGTX has burned cash in almost every quarter: −$3M over the past year, against −$121M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MGTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
MGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +3.1M shares |
| 1 year | +20% | +15.9M shares |
| 3 years | +63% | +37.4M shares |
| 5 years | +119% | +52.7M shares |
| Available history | +192% | +63.7M shares |
MGTX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $18.2M |
| Q4 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
MGTX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over MGTX on leverage, with a lower net debt burden relative to earnings.
MGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.5 | Neutral |
| Stochastic | 6.8 | Oversold |
MGTX's weekly RSI is 38 (neutral) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MGTX PE vs Healthcare Sector
| Metric | MGTX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
MGTX has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.77 | 10% below |
| 20 week MA | $11.8 | 26% below |
| 50 week MA | $9.90 | 11% below |
| 100 week MA | $8.49 | 3.5% above |
| 200 week MA | $7.11 | 24% above |
MGTX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 24% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MGTX on trend strength, trading above more of its moving averages.
MGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.1 | $16.4 | -18% |
| 2021 | $16.4 | $22.4 | +36% |
| 2022 | $22.4 | $6.01 | -73% |
| 2023 | $6.01 | $7.02 | +17% |
| 2024 | $7.02 | $6.21 | -12% |
| 2025 | $6.21 | $7.97 | +28% |
| 2026 YTD | $7.97 | $8.79 | +10% |
MGTX has finished lower in three of the last six years. It's up 10% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MGTX on returns for 2026, with the stronger performance.